Metastatic Cancer Models

Metastatic cancer models are crucial for studying tumor progression, immune system interactions, and drug resistance in cancers that spread beyond the primary tumor site. These models help in evaluating:

1) Mechanisms of metastasis (e.g., epithelial-mesenchymal transition, circulating tumor cells).
2) Therapies targeting metastatic disease (e.g., anti-metastatic agents, immunotherapies).
3) Tumor microenvironment (TME) influences on metastasis.

MuriPhys is uniquely positioned to conduct high-quality metastatic cancer studies with expertise in experimental metastasis techniques such as intravenous, intracardiac, and orthotopic injections. Our in vivo imaging capabilities, including bioluminescence and fluorescence, enable real-time monitoring of tumor spread and treatment response. With advanced surgical skills, and precision drug administration, MuriPhys provides a comprehensive platform for studying the complexity of metastatic disease in translational oncology research.

SPEAK TO A SCIENTIST

BOOK A MEETING

Metastatic models can be developed using syngeneic, xenograft, and genetically engineered approaches. Below are different types of metastatic models commonly used by MuriPhys researchers categorized by their methodology and applications.

Types of Metastatic Models

A. Spontaneous Metastasis Models

• Tumor cells or tissues are implanted at the primary tumor site (e.g., breast, lung, pancreas).
• Tumor metastasizes naturally over time to secondary organs.
• Best for studying metastasis dynamics and immune interactions.
• Common models:
• 4T1 breast cancer (BALB/c mouse) → Metastasizes to lung, liver, brain.
• B16-F10 melanoma (C57BL/6 mouse) → Metastasizes to lung.
• LLC1 lung cancer (C57BL/6 mouse) → Metastasizes to lung and liver.
• Panc02 pancreatic cancer (C57BL/6 mouse) → Metastasizes to liver.

B. Experimental (Injection-Based) Metastasis Models

• Tumor cells are injected directly into circulation or specific organs to induce metastasis.
• Faster metastasis development compared to spontaneous models.
• Routes of injection:
• Intravenous (IV) → Lung metastases (e.g., B16-F10 melanoma).
• Intracardiac (IC) → Bone, brain, and systemic metastases.
• Intrasplenic (IS) → Liver metastases (e.g., colorectal cancer).
• Intraperitoneal (IP) → Ovarian cancer dissemination.

C. Orthotopic Metastasis Models

• Tumor cells are implanted in the organ of origin to better recapitulate tumor behavior.
• Allows for natural invasion and metastasis to distant organs.
• Common models:
• Breast cancer (4T1, MDA-MB-231) → Lung, brain metastases.
• Pancreatic cancer (Panc02, PDX models) → Liver metastases.
• Glioblastoma (GL261, patient-derived glioma models) → Brain invasion.

D. Genetically Engineered Metastatic Models (GEMMs)

• Mice engineered to develop spontaneous tumors that metastasize naturally.
• Oncogene activation (e.g., KRAS, MYC) or tumor suppressor loss (e.g., p53, PTEN) triggers metastasis.
• Examples:
• MMTV-PyMT (breast cancer, C57BL/6 mouse) → Lung metastases.
• KPC model (pancreatic cancer, KRAS^G12D/p53^R172H, C57BL/6) → Liver, lung metastases.

Advanced Drug Administration & Serial Injections

We specialize in the following routes of administration:

Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Intrathecal (IT), Intra Peritoneal (IP), Oral Gavage (PO), Topical, Slow-infusion and Continuous Infusions – Ensuring accurate systemic or localized therapeutic exposure.

Serial Injections – Enabling longitudinal drug administration studies to monitor treatment effects over time.

Quality Control: Mycoplasma Testing

To ensure the highest standards in preclinical research, all cell lines used in our studies undergo rigorous mycoplasma testing, preventing contamination and ensuring reliable, reproducible results.

At MuriPhys, we are dedicated to accelerating oncology drug discovery with cutting-edge preclinical solutions. Contact us today to discuss how we can support your oncology research!

Partner with Us to Advance Your Oncology Research
By choosing our comprehensive services, you gain a trusted partner committed to de-risking your projects and accelerating your path to clinical success. Contact us today to discover how we can empower your oncology research and help bring innovative therapies to patients faster.